Policy & Regulation
Precision Biosciences initiates patient enrollment in PBGENE-DMD clinical study
29 April 2026 - Gene editing company Precision BioSciences Inc (Nasdaq:DTIL) reported on Wednesday that it has activated the first clinical trial site and commenced patient enrollment in its Phase 1/2...
Immunome submits FDA application for varegacestat following strong Phase 3 results
29 April 2026 - Biotechnology company Immunome Inc (Nasdaq:IMNM) disclosed on Wednesday that it has submitted a New Drug Application to the U.S. Food and Drug Administration for varegacestat, an oral ...
HUTCHMED secures priority review for sovleplenib NDA in China
29 April 2026 - Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq:HCM) (AIM:HCM) (HKEX:13) announced on Wednesday that the New Drug Application for sovleplenib has been accepted for review an...
Chiesi Group to acquire KalVista Pharmaceuticals for USD1.9bn in rare disease expansion strategy
29 April 2026 - Chiesi Group, an international research-focused biopharmaceutical group and certified B Corp, announced on Wednesday that it has entered into a definitive agreement to acquire biopharm...
Circio partners with USC to advance non-viral RNA delivery technologies
29 April 2026 - Biotechnology company Circio Holding ASA (OSE:CRNA) said on Wednesday that it has entered into a research collaboration with Universidad de Santiago de Compostela through its TraffikGe...
Cirius Therapeutics introduces gestational diabetes initiative
29 April 2026 - Clinical-stage pharmaceutical company Cirius Therapeutics Incannounced on Tuesday a planning grant from the Gates Foundation to advance the development of CIR-0602K as a potential post...